My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
November 2008
Vol. 18 No. 11
Patient Care and Science
How to Treat MRSA? What Makes it Virulent?

Methicillin-resistant Staphylococcus aureus (MRSA) continues to develop resistance to a range of therapies, according an update on the epidemic at the 48th ICAAC/IDSA 46th Annual Meeting in October. In other developments updated at the session, Panton-Valentine leukocidin does not appear to be the primary virulence factor.

With nearly 100,000 invasive infections and 19,000 deaths each year, MRSA is “the epidemic of our time,” said Robert Daum, MD, of the University of Chicago Medical Center.

Community-associated (CA) MRSA, particularly the USA300 strain, has become the leading cause of emergency department visits for skin and soft tissue infections (SSTI) in most of the United States, and the rise of USA300 coincides with a sharp increase in SSTI hospitalizations, according to the Centers for Disease Control and Prevention’s Rachel Gorwitz, MD, MPH. The increasing incidence of MRSA community-acquired pneumonia is also becoming a serious concern. While most invasive MRSA infections are associated with health care, onset of infection predominantly occurs in the community, Dr. Gorwitz said.

The presence of Panton-Valentine leukocidin (PVL) is associated with epidemic MRSA strains and is a known virulence factor. However, Frank DeLeo, PhD, of the National Institute of Allergy and Infectious Diseases (NIAID), presented data suggesting PVL is not the primary virulence factor. Instead, a group of proteins called phenol-soluble modulin-like peptides (PSM), not PVL, appeared to promote severe SSTIs, pneumonia, and neutrophil lysis in animal models.

The primary management for CA-MRSA SSTIs is incision and drainage (I&D), Dr. Daum said. He noted that although most respondents to a recently published survey said they would add anti-MRSA antibiotics, there is very limited data on the efficacy of antibiotics for these infections. An NIAID-sponsored study is underway to provide some of the missing data. (IDSA urged NIAID to undertake a study like this one.)

Clindamycin is one of the top choices for empiric therapy of SSTIs, but reports of clindamycin-resistant MRSA are increasing. Some strains carry the erm gene that confers resistance to erythromycin and—sometimes—clindamycin. To assess clindamycin susceptibility, Dr. Daum strongly recommended performing a “D test,” which determines whether clindamycin resistance can be turned on. A positive D test generally—but not always—indicates clindamycin resistance. Before changing therapy, Dr. Daum advised, “Go to the patient’s bedside and see if they are already cured.”

For MRSA pneumonia, vancomycin remains the mainstay of treatment, Dr. Daum said.  But vancomycin has poor bacteriocidal activity, does not penetrate tissues well, and resistance is increasing. There are a few options beyond vancomycin, but all have serious shortcomings. Daptomycin is perhaps the next-best option, but elevates creatine phosphokinase levels. Linezolid has problems with hematologic toxicity, neuropathies, and lactic acidosis, especially with prolonged use. Daptomycin and tigecycline are not recommended for pediatric cases. There are reports of resistance to all these drugs. Drugs in clinical development all have serious shortcomings as well.

“I believe we need a Staphylococcus aureus vaccine,” Dr. Daum concluded. “I think the attack rate is high enough, and the antibiotic resistance problem demands it.”

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


The IDSA Journal Club is on vacation.
Top Stories
ICAAC/IDSA Symposium Highlights Alternatives to Vancomycin
New ARVs Offer Virologic Suppression in Most Patients
ID Physicians Can Increase Medicare Payments in 2009
From the President
Change is in the Air
Patient Care and Science
Antimicrobial Stewardship Programs, National Campaigns Curb Usage
How to Treat MRSA? What Makes it Virulent?
ACIP Recommends Pneumococcal Vaccine for Cigarette Smokers
In the IDSA Journals
EIN: When is it OK for TB Patients to Use TNF inhibitors?
Drug Approvals, Recalls, Adverse Events Update
Practice Management
Infusion and Injection CPT Codes Changed
2009 Clinical Practice Meeting in San Diego
Global ID
WHO Promotes “Three I’s” for HIV/TB Co-infection
Policy and Advocacy
IM Subspecialists Lend Support to Adult Immunization
FDA Advisory Groups Warn Against Home Stockpiling of Antivirals for Pandemic Flu
Education and Resources
Seasonal and Pandemic Influenza 2008 Monograph Now Available
How to Claim CME Credit from ICAAC/IDSA
Your Colleagues
Welcome, New IDSA Members!

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.